Skip to main content

Lippoldt Darin's Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Feb 14, 2025

Accession no.
0000914475-25-000065
Filed
Feb 14, 2025
Trade date
Feb 12-13, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $255.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lippoldt DarinCIK 0001504783Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 12, 2025Common StockGGiftDisposed−190$0.00$041,489Direct
Feb 13, 2025Common StockMOption exerciseAcquired+2,083$0.00$043,572Direct
Feb 13, 2025Common StockSSaleDisposed−1,098$116.76−$128,202.4842,474Direct
Feb 13, 2025Common StockMOption exerciseAcquired+2,017$0.00$044,491Direct
Feb 13, 2025Common StockSSaleDisposed−1,086$116.75−$126,790.543,405Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 12, 2025Common StockAGrant or awardAcquired+38,252$0.00$038,252Direct
Feb 12, 2025Common StockAGrant or awardAcquired+7,169$0.00$07,169Direct
Feb 13, 2025Common StockMOption exerciseDisposed−2,083$0.00$04,166Direct
Feb 13, 2025Common StockMOption exerciseDisposed−2,017$0.00$06,053Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)